VKTX: Results from Phase 2 Trial of VK5211 in Hip Fracture in mid-2017
Yahoo! Finance USA,
By David Bautz, PhD NASDAQ:VKTX Business Update Viking Therapeutics, Inc. ( VKTX) is a biopharmaceutical company developing…
VKTX: Additional Data Show Promise of VK2809 in Lipid Disorders…
Yahoo! Finance USA,
By David Bautz, PhD NASDAQ:VKTX Business Update Viking Therapeutics, Inc. (VKTX) is a biopharmaceutical company developing…
VKTX: Data From Phase 2 Studies of VK2809 for Hypercholersterolemia and VK5211 for Hip Fracture to be Reported in 2Q17
Yahoo! Finance USA,
VK2809 Update VK2809 (formerly known as MB07811) is a novel, orally available, selective thyroid hormone receptor (TR) agonist…
VKTX: Phase 2 Study of VK5211 for Hip Fracture Ongoing; Phase 2 Study of VK2809 for Hypercholersterolemia to Commence in mid-2016
Yahoo! Finance USA,
By David Bautz, PhD NASDAQ:VKTX Business Update VK5211 Update Viking’s (VKTX) lead drug candidate is VK5211, a third-generation…
VKTX: Phase 2 Clinical Trial of VK2809 in Hypercholesterolemia to Initiate Mid-2016…
Yahoo! Finance USA,
By 1 hour ago By David Bautz, PhD NASDAQ:VKTX Financial Update On March 8, 2016, Viking Therapeutics, Inc.